Diacerein

證據等級: L5

預測適應症: 0 個

Diacerein: Drug Repurposing Evaluation Report

One-Sentence Summary

Diacerein is an anthraquinone derivative currently marketed in Malaysia, primarily used for the symptomatic treatment of osteoarthritis. No predicted new indications were generated by the TxGNN model in this evaluation cycle, and significant data gaps remain in mechanism of action, safety, and regulatory label details.

Quick Overview

Item	Content
Original Indication	Not available (license details pending)
Predicted New Indication	— (No TxGNN prediction generated)
TxGNN Prediction Score	N/A
Evidence Level	L5 (No predictions or supporting evidence)
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, the TxGNN model did not generate any predicted new indications for Diacerein. This may be due to insufficient mapping between the drug’s DrugBank entry (DB11994) and the knowledge graph nodes, or limited relational data in the KG for this compound.

Detailed mechanism of action (MOA) data is not available in this evidence pack. Based on publicly known information, Diacerein is an interleukin-1β (IL-1β) inhibitor belonging to the anthraquinone class. It is a pro-drug that is metabolised to its active form, rhein, which exerts anti-inflammatory and cartilage-protective effects. Its approved use in osteoarthritis has been established in multiple markets; however, without a TxGNN prediction output, no mechanistic bridging to a new indication can be assessed at this time.

The absence of a prediction does not imply the drug lacks repurposing potential — it indicates that the current data pipeline requires additional input (e.g., improved DrugBank-to-KG mapping, or enriched indication text for disease matching) before the model can generate candidate indications.

Clinical Trial Evidence

Currently no TxGNN-predicted indication exists for Diacerein; therefore, no targeted clinical trial search was performed.

Literature Evidence

Currently no TxGNN-predicted indication exists for Diacerein; therefore, no targeted literature search was performed.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Pending retrieval)	(Pending retrieval)	(Pending retrieval)	(Pending retrieval)

Note: One registration was identified in the NPRA query (query date: 2026-03-27), but the detailed license fields (authorization number, product name, dosage form, approved indication) were not populated in this evidence pack. These details need to be retrieved from the NPRA database.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN-predicted indications were generated for Diacerein, and critical data gaps exist across MOA, regulatory label details, and safety information. The evaluation cannot proceed to candidate assessment without these foundational inputs.

To proceed, the following is needed:

Retrieve NPRA license details — Query the NPRA database for full registration information (authorization number, product name, dosage form, approved indication text)
Fill MOA data gap (DG002) — Query DrugBank API for Diacerein’s mechanism of action, pharmacodynamics, and target information
Fill safety data gap (DG001) — Download and parse the package insert PDF from the regulatory authority for warnings, contraindications, and precautions
Investigate KG mapping — Verify that Diacerein (DB11994) is correctly mapped to the TxGNN knowledge graph nodes; check node.csv for the presence of this DrugBank ID and confirm edge connectivity in kg.csv
Re-run TxGNN prediction — Once mapping is confirmed and data gaps are resolved, re-execute the KG and DL prediction pipelines to generate candidate indications

This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.